The SGB board of directors includes experienced entrepreneurs and representatives from leading venture capital firms, energy and biotechnology companies.
Dr. Jerry Caulder is managing director at Finistere Ventures. Dr. Caulder has an unparalleled record in the life sciences industries. During his fifteen years at Monsanto, he held numerous management positions and was responsible for overseeing the company's early venture investments and the launch of new agricultural products globally. In 1984, he became chairman and CEO of Mycogen, a start-up plant sciences company. Under his direction, Mycogen had a successful IPO and was acquired by Dow Agrosciences with a market capitalization of more than $1.2 billion. Since the acquisition, he has held leadership positions in a number of highly successful life science companies including Myelos Pharmaceuticals, a therapeutic drug discovery company focusing on the treatment of diabetic neuropathy, and Advanced Stent Technologies, which focused on the development of a dedicated coronary bifurcation stent. His most recent success was as Chairman of Athenix, Inc., a venture-backed plant sciences company acquired by Bayer Crop Sciences in November 2009 for $400 million. He has been involved in the formation of many local, state and national biotechnology groups and initiatives, including serving as Chairman of BIO, the world's largest biotechnology advocacy and business development organization.